Viral pneumonia damages bronchial epithelium and alveolar cells directly; immune response (cytotoxic T cells) may amplify epithelial injury. Inflammatory exudation and loss of surfactant-producing type II pneumocytes impair compliance and gas exchange. Secondary bacterial superinfection worsens prognosis.
From your study of the respiratory system, you know that the alveolus is where gas exchange actually occurs: a razor-thin interface between inhaled air and the pulmonary capillaries, lined by type I pneumocytes (flat cells optimized for gas diffusion) and type II pneumocytes (cuboidal cells that produce surfactant, the phospholipid film that reduces surface tension and prevents alveolar collapse). Viral pneumonia is best understood as a two-stage attack on this delicate interface—a direct cytopathic phase followed by an immune-mediated amplification phase—with the relative contribution of each varying by pathogen and host.
In the initial phase, respiratory viruses (influenza, SARS-CoV-2, RSV, parainfluenza) infect bronchial and alveolar epithelial cells after binding surface receptors. The virus replicates intracellularly, and the infected cell's machinery is co-opted until the cell lyses or undergoes apoptosis. Type II pneumocytes are particularly vulnerable because they express high levels of the receptors that many respiratory viruses target—influenza hemagglutinin binds sialic acid residues, SARS-CoV-2 spike binds ACE2, which is highly expressed on type II cells. As type II pneumocytes die, surfactant production falls. Without surfactant, the surface tension at the air-liquid interface rises, smaller alveoli tend to collapse (atelectasis), and the remaining open alveoli require greater inspiratory pressure to expand—reducing lung compliance and increasing the work of breathing. This is the earliest mechanical consequence of viral pneumonia.
From your adaptive immune response studies, you know that cytotoxic CD8+ T cells (CTLs) recognize virally infected cells presenting peptide antigens on MHC class I and kill them by releasing perforin and granzymes. In viral pneumonia, this is a double-edged mechanism: CTLs are essential for viral clearance, but because they target any virally infected alveolar cell—not just cells that have completed viral replication—they amplify the epithelial destruction. The resulting inflammatory exudate (fluid, fibrin, macrophages, neutrophils) floods the alveolar space, replacing air with liquid and creating the consolidation visible on chest X-ray. Fluid in the alveolus means those alveoli are perfused but not ventilated—a ventilation-perfusion (V/Q) mismatch that is the direct cause of the hypoxemia patients experience. In severe cases, inflammatory cytokines (IL-6, TNF-α, IFN-γ) released by innate immune cells and activated T cells drive a cytokine storm that amplifies vascular permeability, causing non-cardiogenic pulmonary edema and acute respiratory distress syndrome (ARDS).
Secondary bacterial superinfection—classically with Streptococcus pneumoniae, Staphylococcus aureus, or Haemophilus influenzae following influenza—worsens outcomes through several converging mechanisms. Viral infection disrupts the mucociliary escalator (damaged ciliated bronchial epithelium cannot move mucus and bacteria out of the airways), reduces local innate immune function (type I interferon responses induced by viruses also transiently suppress antimicrobial defenses), and exposes basement membrane proteins that bacteria can adhere to. The bacterial superinfection adds a second inflammatory insult on top of already damaged epithelium, and the bacterial toxins—particularly pore-forming toxins from S. aureus—can independently lyse pneumocytes and endothelial cells. This explains the historical observation that the most lethal pandemic influenza deaths (including 1918) often showed evidence of secondary bacterial pneumonia on autopsy—the viral injury set the stage, but bacterial superinfection frequently delivered the fatal blow.
No topics depend on this one yet.